Supernus Pharmaceuticals reported $400.38M in Loan Capital for its fiscal quarter ending in March of 2022.





Loan Capital Change Date
Abbott USD 29.45B 152M Sep/2026
ANI Pharmaceuticals USD 274.31M 5.84M Sep/2026
Aurora Cannabis CAD 16.81M 1.32M Jun/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Canopy Growth CAD 211.38M 5.74M Jun/2026
Cara Therapeutics USD 0 0 Mar/2025
Eisai JPY 184.62B 19M Sep/2026
Eli Lilly USD 46.99B 872M Sep/2026
Novo Nordisk DKK 121.79B 2.62B Jun/2026
Perrigo USD 3.28B 600K Sep/2026
Pfizer USD 60B 498M Sep/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
United Therapeutics USD 100M 100M Jun/2024
Xeris Pharmaceuticals USD 189.71M 906K Sep/2026